NRP1 and pulmonary arterial hypertension: These findings establish EP300 as a mechanistic driver of endothelial dysfunction in PAH, and highlight the EP300-H3K27ac-NRP1 axis as a promising therapeutic approach to prevent PAH onset or attenuate PAH severity.